FDA Updates Highlighting the Latest Cancer Treatments

出处
期刊:Oncology times [Wolters Kluwer]
卷期号:41 (7): 23-30
标识
DOI:10.1097/01.cot.0000557613.23937.e9
摘要

Trifluridine/Tipiracil Approved for Gastric or GEJ AdenocarcinomaFDA; oncology: FDA; oncologyThe FDA has approved trifluridine/tipiracil as a treatment for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu targeted therapy. The approval follows an FDA Priority Review designation and is based on data from a global, randomized, phase III TAGS trial evaluating trifluridine/tipiracil plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated advanced gastric cancer or GEJ adenocarcinoma following progression or intolerance to previous lines of standard therapy. The trial met its primary and secondary endpoints demonstrating prolonged overall survival (OS) with trifluridine/tipiracil versus placebo, and a safety profile consistent with prior experience with this drug. Full results from the TAGS trial were presented at the European Society for Medical Oncology 2018 Congress with a simultaneous publication in The Lancet Oncology (2018;19(11):1437-1438). This approval expands the current indication for trifluridine/tipiracil in the U.S., where it is currently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with standard chemotherapy, based on results obtained in the RECOURSE trial. TAGS (TAS-102 Gastric Study) is a global, randomized, double-blind phase III study evaluating trifluridine/tipiracil (TAS-102) plus BSC versus placebo plus BSC in patients with metastatic gastric or GEJ cancer, refractory to standard treatments. The primary endpoint in the TAGS trial was OS, and the main secondary endpoint measures included progression-free survival, safety, and tolerability, as well as quality of life. The study enrolled 507 adult patients with metastatic gastric or GEJ cancer who had previously received at least two prior regimens for advanced disease and it was conducted in 17 countries and 110 sites around the world. Daratumumab Split-Dosing Regimen Approved for Multiple Myeloma The FDA has approved a split-dosing regimen for daratumumab, providing health care professionals and patients with multiple myeloma an option to split the first infusion over 2 consecutive days. The approval is based on data from the phase Ib EQUULEUS (MMY1001) clinical study, which demonstrated daratumumab pharmacokinetic concentrations were comparable at the end of weekly dosing, regardless of whether the first dose was administered as a split infusion or as a single infusion. The global, multi-arm study evaluated daratumumab in combination with various treatment regimens. Splitting the first dose of daratumumab over 2 consecutive days effectively reduced the duration of the first infusion and resulted in a similar rate and pattern of infusion reactions. Data from the study demonstrated that daratumumab concentrations were comparable at the end of weekly dosing regardless of whether the first 16 mg/kg dose was administered as a split infusion or single first infusion. The safety profile of daratumumab was comparable when administered initially as a split or single dose, and no new safety events were observed with a split first dose. This approval follows approvals in Canada and the European Union in December 2018 for the daratumumab initial infusion split-dosing regimen. Daratumumab is the first and only CD38-directed antibody to receive regulatory approval to treat multiple myeloma. In the U.S., daratumumab first received FDA approval in November 2015 as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. The treatment received additional approvals in November 2016 in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. In June 2017, daratumumab received approval in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a PI. Most recently, in May 2018, daratumumab received approval in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant, making it the first monoclonal antibody approved for newly diagnosed patients with this disease. Priority Review Granted for Fedratinib New Drug Application in Myelofibrosis The FDA has accepted the New Drug Application (NDA) for fedratinib and granted Priority Review. Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis. Under the Prescription Drug User Fee Act, the FDA has set its action date as Sept. 3, 2019. The NDA for fedratinib is based on results from a randomized, placebo-controlled, phase III trial (JAKARTA) in patients with primary or secondary myelofibrosis, as well as a single-arm, open-label phase II trial (JAKARTA2) in patients with primary or secondary myelofibrosis previously exposed to ruxolitinib, the only FDA-approved treatment for the disease. Results of these two trials have been previously published in peer-reviewed journals. The FDA has also provided fedratinib Orphan Drug designation for the treatment of secondary and primary myelofibrosis. JAKARTA is a pivotal, phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy of daily oral doses (400 mg or 500 mg) of fedratinib compared with placebo in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with splenomegaly. The study included 289 subjects across 94 sites in 24 countries. The primary endpoint was spleen response rate, defined as the proportion of patients who had a reduction in spleen volume of at least 35 percent after six 1-month treatment cycles with an MRI or CT scan 4 weeks later. Secondary endpoints included symptom response rate, defined as the proportion of patients with a 50 percent or greater reduction in Total Symptom Score after six 1-month treatment cycles as measured by the modified Myelofibrosis Symptoms Assessment Form v2.0 diary. JAKARTA2 evaluated the efficacy of a once-daily dose of fedratinib (400 mg starting dose) in patients previously treated with ruxolitinib and with a diagnosis of intermediate-1 with symptoms, intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. The study included 97 subjects across 40 sites in 10 countries. FDA placed a clinical hold on the fedratinib program in November 2013 after potential cases of Wernicke encephalopathy were reported among subjects (approximately 1%) in clinical trials. The FDA removed the clinical hold in August 2017. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher potency for JAK2 over family members JAK1, JAK3, and TYK2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. In cell models expressing mutationally active JAK2 or FLT3, fedratinib reduced phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited cell proliferation, and induced apoptotic cell death. In mouse models of JAK2V617F-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT3/5, increased survival and improved disease-associated symptoms, including reduction of white blood cells, hematocrit, splenomegaly, and fibrosis. Lenalidomide Receives Priority Review for Follicular & Marginal Zone Lymphoma The FDA has granted Priority Review designation for the supplemental New Drug Application (sNDA) for lenalidomide in combination with rituximab (R2) for the treatment of patients with previously treated follicular and marginal zone lymphoma. Under the Prescription Drug User Fee Act, the FDA has set its action date as June 27, 2019. The sNDA is based on results from the randomized, double-blind, phase III AUGMENT study, which evaluated the efficacy and safety of the investigational R2 combination versus rituximab plus placebo in patients with relapsed/refractory follicular and marginal zone lymphoma. Results from the study were presented at the 2018 American Society of Hematology Annual Meeting. AUGMENT is a phase III, randomized, double-blind clinical trial evaluating the efficacy and safety of lenalidomide in combination with R2 versus rituximab plus placebo in patients with relapsed/refractory follicular and marginal zone lymphoma. The primary endpoint was progression-free survival, defined as the time from date of randomization to the first observation of disease progression or death due to any cause. Secondary endpoints included overall response rate, durable complete response rate, complete response rate, duration of response, duration of complete response, overall survival, event-free survival, and time to next anti-lymphoma therapy. Orphan Drug Designation for Etoposide Toniribate in R/R Biliary Tract Cancer The FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma. Etoposide toniribate has shown encouraging data in phase II trials and this data has been key in securing the ODD. This news is in addition to the European Medicines Agency also granting orphan designation on June 4, 2014. As with the FDA, this designation allows protocol assistance, reduced fees, and 10-years marketing exclusivity in that disease after approval. It can also lead to speedier reimbursement in many EU member states. Etoposide toniribate is a novel topoisomerase II inhibitor in clinical development for the treatment of relapsed/refractory biliary tract cancer. This small molecule drug is designed to work by metabolizing into its active form through enzymes in the gastrointestinal tract that are active in cancer cells. Specifically, etoposide toniribate is hydrolyzed at the site of the tumor by carboxylesterase, an enzyme expressed by some tumors, to produce activated etoposide. Activated etoposide binds to and inhibits topoisomerase II, which is often elevated in tumors, resulting in double-strand breaks in tumor DNA. Damage to the tumor DNA induces apoptosis. Results of a randomized phase II trial of 23 patients with refractory, metastatic, unresectable biliary tract cancer who had relapsed following treatment with gemcitabine/cisplatin showed a 1-year overall survival of 44 percent with etoposide toniribate versus 11.3 percent with best supportive care (BSC). Overall, 55.6 percent of patients met the primary endpoint of disease control compared with 20.0 percent who received BSC. In the trial, etoposide toniribate was generally well-tolerated with a predictable toxicity profile. The most common drug-related adverse events were neutropenia, leukopenia, thrombocytopenia, anemia, alopecia, fatigue, and abdominal pain. Biliary tract cancer is a rare tumor with approximately 8,000 patients diagnosed in the U.S. every year and 10,571 in Europe. The FDA grants ODD status to medicines intended for the treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of care is generally palliative. The 5-year survival rates for patients with biliary tract cancer are very low, approximately 15 percent. Biliary tract cancer can develop in any part of the bile duct system. Nearly two out of three people with biliary tract cancer are age 65 or older at the time of diagnosis, and the average age is 70. Risk factors for biliary tract cancer include age older than 65 years, alcohol consumption, bile duct stones, cirrhosis, diabetes, a family history of cholangiocarcinoma, inflammatory bowel disease (ulcerative colitis and Crohn's disease), obesity, and long-term infection with hepatitis B or C virus.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被科研通管家采纳,获得10
刚刚
天天向上的应助被科研通管家采纳,获得10
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
不爱喝酒的应助被科研通管家采纳,获得10
1秒前
天天快乐的应助被科研通管家采纳,获得10
1秒前
gczl完成签到,获得积分10
1秒前
科目三的应助被科研通管家采纳,获得10
1秒前
小水滴发布了新的文献求助10
1秒前
李爱国的应助被科研通管家采纳,获得10
1秒前
AC赵先生完成签到,获得积分10
1秒前
星辰大海的应助被科研通管家采纳,获得10
1秒前
搜集达人的应助被科研通管家采纳,获得10
1秒前
无极微光的应助被科研通管家采纳,获得20
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
qianhong完成签到,获得积分10
2秒前
2秒前
科研通AI65的应助被科研通管家采纳,获得10
2秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
充电宝的应助被科研通管家采纳,获得10
2秒前
小二郎的应助被科研通管家采纳,获得10
2秒前
syvshc的应助被科研通管家采纳,获得10
2秒前
3秒前
Jun的应助被科研通管家采纳,获得10
3秒前
所所的应助被科研通管家采纳,获得10
3秒前
CodeCraft的应助被科研通管家采纳,获得10
3秒前
wyfuuu完成签到,获得积分10
3秒前
3秒前
SciGPT的应助被科研通管家采纳,获得10
3秒前
科目三的应助被科研通管家采纳,获得10
3秒前
JamesPei的应助被科研通管家采纳,获得10
3秒前
Lucas的应助被科研通管家采纳,获得10
4秒前
鸟窝的应助被科研通管家采纳,获得10
4秒前
ding的应助被科研通管家采纳,获得10
4秒前
阿申爱乐的应助被科研通管家采纳,获得30
4秒前
4秒前
顾矜的应助被科研通管家采纳,获得10
4秒前
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565